News

Acarix accelerates US commercialization into 30 additional states

Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announced a strategic sales partnership with CompleMed, LLC, a national sales organization focusing on the US cardiology market. This partnership expands Acarix sales organization with 16 additional sales teams covering initially 30 new states across the United States, reaching a current geographic market coverage of 43 states.

"We are thrilled to be collaborating with Acarix, whose reputation in the US market continues to grow”, stated Mike Buie, President of CompleMed. “The CADScor System has captured our attention as an exceptional solution for early assessment of patients with non-acute chest pain, which is an increasingly complex and resource demanding issue in the US healthcare system. We look forward to making a difference together with the Acarix team."

"We are excited to announce our new partnership with CompleMed, whose sizeable and capable sales team will enable us to expand our geographic coverage rapidly into additional states. We are eager to expand our US footprint to continue to build on our momentum and bring the CADScor System to even more patients. This well-planned expansion aligns well with our growth strategy and reaffirms our commitment to delivering exceptional care to patients." said Acarix President & CEO, Helen Ljungdahl Round.